Company profile for Urica Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Urica Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia. Urica acquired the rights to develop and commercialize Dotinurad, a potentially best-in-class URAT1 inhibitor, in the United States, United Kingdom, European Union, Canada, Middle East and North Africa (MENA) and Turke...
Urica Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia. Urica acquired the rights to develop and commercialize Dotinurad, a potentially best-in-class URAT1 inhibitor, in the United States, United Kingdom, European Union, Canada, Middle East and North Africa (MENA) and Turkey from Fuji Yakuhin. Dotinurad has been approved to treat gout and hyperuricemia in Japan and is currently in Phase 1 clinical trial in the United States.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/21/3170212/28889/en/Fortress-Biotech-and-Subsidiary-Urica-Therapeutics-Announce-First-Patients-Dosed-in-Crystalys-Therapeutics-Global-Phase-3-Trials-of-Dotinurad-for-the-Treatment-of-Gout.html

GLOBENEWSWIRE
21 Oct 2025

https://www.globenewswire.com/news-release/2025/10/01/3159491/28889/en/Fortress-Biotech-and-Subsidiary-Urica-Therapeutics-Announce-Crystalys-Therapeutics-205-Million-Series-A-Financing.html

GLOBENEWSWIRE
01 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty